Naltrexone
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 25/100
25
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Methamphetamine Dependence
Conditions
Methamphetamine Dependence
Trial Timeline
Sep 1, 2009 → Sep 1, 2012
NCT ID
NCT00984360About Naltrexone
Naltrexone is a phase 2 stage product being developed by Pacific Biosciences for Methamphetamine Dependence. The current trial status is completed. This product is registered under clinical trial identifier NCT00984360. Target conditions include Methamphetamine Dependence.
What happened to similar drugs?
1 of 1 similar drugs in Methamphetamine Dependence were approved
Approved (1) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
12
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00984360 | Phase 2 | Completed |
Competing Products
6 competing products in Methamphetamine Dependence
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| CPP-109 vigabatrin + Matching Placebo | Catalyst Pharmaceuticals | Phase 2 | 21 |
| A single oral 5 mg of duterium labeled methamphetamine | Pacific Biosciences | Approved | 25 |
| Dextroamphetamine + Placebo | Pacific Biosciences | Phase 2 | 25 |
| modafinil | Pacific Biosciences | Phase 2 | 25 |
| Modafinil | Pacific Biosciences | Phase 2 | 25 |
| Ibudilast 20mg + Ibudilast 50mg + Placebo oral tablet | MediciNova | Phase 1 | 19 |